Cabozantinib Does Not Demonstrate Improvements in Advanced Prostate Cancer
In a recent study, the targeted agent cabozantinib did not demonstrate an improvement in outcomes compared to prednisone, among men […]
FDA Approves New Imaging Agent for Detection of Recurrent Prostate Cancer
The United States Food and Drug Administration (FDA) has approved Axumin (fluciclovine F 18), an radioactive agent, to be used […]
Xtandi® Improves Survival in Advanced Prostate Cancer
The agent Xtandi® (enzalutamide) improves survival and reduces the time to cancer progression compared to Casodex® (bicalutamide) among men with […]
Combined Hormone and Radiation Therapy Superior to Radiation Alone for Prostate Cancer Recurring After Prostatectomy
The addition of two years of anti-androgen therapy (AAT) to radiation therapy reduces the risk of death caused by prostate […]
Adding Zytiga to Prednisone Improves Survival and Pain in Chemotherapy-Naive Castration-Resistant Prostate Cancer Patients
CancerConnect News: The addition of Zytiga® (abiraterone acetate) to prednisone significantly improves survival of chemotherapy-naive patients whose prostate cancer has […]
Xofigo Extends Survival in Hormone-Refractory Prostate Cancer
For patients with advanced hormone-refractory prostate cancer, the agent Xofigo® (radium-223) appears similarly effective in patients who have and have […]
Bayer and Orion Initiate Phase III Trial of Novel Prostate Cancer Agent ODM-201 in Men with High-Risk Non-Metastatic Castration-Resistant Prostate Cancer
Bayer HealthCare and Orion Corporation, a pharmaceutical company based in Espoo, Finland, have begun to enroll patients in a Phase […]
FDA Approves Use of Xtandi for Chemotherapy Naïve Men With Advanced Prostate Cancer
The FDA approved the use of Xtandi® (enzalutamide) in men who have not yet received chemotherapy, significantly expanding the potential […]
New Survey Reveals that Prostate Cancer Impacts Sex Lives More than Any Other Aspect of Patients’ Lives
Washington, DC (September 8, 2014) – A recent survey conducted by ZERO – The End of Prostate Cancer and Ferring […]
September Brings Awareness to Prostate Cancer
Sun Valley, ID & Fort Worth, TX—OMNI Health Media (OMNI) announces the launch of prostate cancer programs for national prostate […]
Cabozantinib Development in Prostate Cancer Halted
Development of the investigational drug cabozantinib that initially showed promise in the treatment of metastatic, hormone-refractory prostate cancer has been […]
Advaxis and Merck Form Collaboration to Evaluate Investigational Combination of Two Novel Immunotherapy Candidates for Advanced Prostate Cancer
Advaxis, Inc.a clinical-stage biotechnology company developing cancer immunotherapies, has entered into a clinical trial collaboration agreement with Merck to evaluate […]
Combination Hormone Therapy Appears Safe and Effective in Reducing Testosterone in Metastatic Prostate Cancer
In a study presented at the 2014 American Society of Clinical Oncologists meeting, researchers reported that the use of two […]
Taxotere Added to Hormone Therapy Improves Overall Survival by 13 Months in Metastatic Prostate Cancer Patients
In a study conducted by researchers at the Dana-Farber Cancer Institute, Taxotere® (docetaxel) administered with androgen-deprivation therapy to metastatic prostate […]
Xtandi Shows Significant Benefit in Chemotherapy-Naïve, Metastatic, Hormone-Refractory Prostate Cancer
Xtandi® (enzalutamide) showed significant survival benefit in men with chemotherapy-naïve, metastatic, hormone-refractory prostate cancer, according to the results of a […]
High Incidence of Many Complications after Surgery or Radiation for Prostate Cancer
Men who undergo surgery or radiation therapy for prostate cancer may face a variety of complications in addition to incontinence […]
Xtandi Improves Survival in Chemotherapy-Naïve, Metastatic, Hormone-Refractory Prostate Cancer
Xtandi® (enzalutamide) improved survival and reduced the risk of radiographic progression in men with chemotherapy-naïve, metastatic, hormone-refractory prostate cancer, according […]
Zytiga Prolongs Time to Pain Progression
The addition of Zytiga® (abiraterone) to prednisone significantly delayed patient-reported pain progression and health-related quality-of-life deterioration compared with prednisone alone […]